• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to "Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis".

作者信息

Lv Fang, Cai Xiaoling, Ji Linong

机构信息

Department of Endocrinology and Metabolism, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China.

Department of Endocrinology and Metabolism, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China.

出版信息

Bone. 2020 May;134:115271. doi: 10.1016/j.bone.2020.115271.

DOI:10.1016/j.bone.2020.115271
PMID:32248982
Abstract
摘要

相似文献

1
Response to "Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis".对“地诺单抗和罗莫索单抗不会增加原发性骨质疏松症患者发生心血管事件的风险：一项荟萃分析的再分析”的回应
Bone. 2020 May;134:115271. doi: 10.1016/j.bone.2020.115271.
2
Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis.地诺单抗和罗莫单抗不会增加原发性骨质疏松症患者发生心血管事件的风险：一项荟萃分析的再分析
Bone. 2020 May;134:115270. doi: 10.1016/j.bone.2020.115270.
3
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.地舒单抗或罗莫佐单抗治疗与原发性骨质疏松症患者心血管事件风险：系统评价和荟萃分析。
Bone. 2020 Jan;130:115121. doi: 10.1016/j.bone.2019.115121. Epub 2019 Oct 31.
4
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.罗莫佐单抗治疗 1 年后序贯地舒单抗治疗 2 年可维持骨折风险降低：FRAME 扩展研究结果。
J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3.
5
[Osteoporosis].[骨质疏松症]
Rev Med Suisse. 2015 Jan 14;11(456-457):108-13.
6
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.罗莫佐单抗的心血管结局和阿仑膦酸钠的保护作用。
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1343-1350. doi: 10.1161/ATVBAHA.119.312371. Epub 2019 May 23.
7
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.罗莫佐单抗治疗绝经后骨质疏松症妇女。
N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.
8
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.罗莫佐单抗治疗 24 个月后序贯地舒单抗或安慰剂治疗 12 个月对骨密度低的绝经后妇女的影响：一项随机、双盲、2 期、平行组研究。
J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.
9
Monoclonal antibodies for treating osteoporosis.治疗骨质疏松症的单克隆抗体。
Expert Opin Biol Ther. 2018 Feb;18(2):149-157. doi: 10.1080/14712598.2018.1401607. Epub 2017 Nov 7.
10
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.FRAME 研究：使用 1 年罗莫佐单抗构建骨骼的基础效应导致转换为地舒单抗后骨折风险持续降低。
J Bone Miner Res. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17.

引用本文的文献

1
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment.硬化素与心血管风险：评估罗莫佐单抗治疗骨质疏松症时的心血管安全性
Biomedicines. 2024 Dec 18;12(12):2880. doi: 10.3390/biomedicines12122880.
2
Advances in Osteoporotic Bone Tissue Engineering.骨质疏松性骨组织工程的进展
J Clin Med. 2021 Jan 12;10(2):253. doi: 10.3390/jcm10020253.